mitochondrial ribosomal protein S33 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored MRPS33P2 profile across patient tissues and cancer cell-line models. MRPS33P2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MRPS33P2 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, MRPS33P2 RNA expression shows 7,188 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UCS, THCA, and CCRCC as cancer lineages where MRPS33P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS33P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS33P2 survival associations across molecular data types. MRPS33P2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS33P2 RNA expression–survival associations across cancer types. High MRPS33P2 expression shows unfavorable associations in UCS, COAD, DLBC, LUAD, UVM and PCPG. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .015). Together, the overview and detailed table identify UCS as the clearest survival context for MRPS33P2 RNA expression.
This table summarizes MRPS33P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS33P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS33P2 shows lower tumor expression in THCA and KIRC and higher tumor expression in KICH, STAD and LIHC. The THCA box plot shows higher MRPS33P2 RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p = .008).
This table shows molecular features associated with MRPS33P2 in patient tissues and cancer cell lines. In patient samples, MRPS33P2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
